Effects of interleukin 6 administration on platelets and haemopoietic progenitor cells in peripheral blood.
Platelet numbers and circulating haemopoietic progenitor cells were examined in 12 patients with advanced malignancies who were receiving recombinant human interleukin-6 (rhIL-6) as part of an investigation of its thrombopoietic effects. Patients received recombinant glycosylated IL-6 by daily subcutaneous injection for 7 consecutive days in doses of 1, 3 or 10 micrograms/kg/day. Platelet numbers increased reaching a peak on days 12-15 with a mean on day 15 of 198.1% of pre-treatment values. This was accompanied by a significant fall in the mean platelet volume (mean decrease of 10.6%, P = 0.0044). No significant correlation was seen between the IL-6 dose and the change in platelet number. No significant differences were observed between pre- and post-treatment levels of circulating erythroid burst-forming units (E-BFU) and granulocyte macrophage colony-forming units (GM-CFU) but a small significant increase was seen in circulating primitive progenitor cells measured in a plastic-adherent (P delta) assay (P = 0.025). As positive controls, a group of patients treated with cyclophosphamide/G-CSF showed significant increases in GM-CFU (P = 0.018), E-BFU (P = 0.018) and P delta progenitors (P = 0.028). These data suggest that the thrombopoietic effects of IL-6 are mediated at a relatively late stage via effects on megakaryocyte differentiation, with a relatively small effect on circulating haemopoietic progenitors.
Clarke
D
D
Imperial Cancer Research Fund, Cancer Medicine Research Fund, St James's University Hospital, Leeds, UK.
Johnson
P W
PW
Banks
R E
RE
Storr
M
M
Kinsey
S E
SE
Johnson
R
R
Morgan
G
G
Gordon
M Y
MY
Illingworth
J M
JM
Perren
T J
TJ
Selby
P J
PJ
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects* / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000627:therapeutic use; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007279:Injections, Subcutaneous; D015850:Interleukin-6 / Q000627:therapeutic use*; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000628:therapy; D010976:Platelet Count / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use
D000970:Antineoplastic Agents; D015850:Interleukin-6; D011994:Recombinant Proteins; D003520:Cyclophosphamide